百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼

格隆汇
9 hours ago
百时美施贵宝和Ono Pharmaceutical已在特拉华州联邦法院对安进提起诉讼,试图阻止安进在美国推出其重磅癌症免疫疗法药物Opdivo的生物类似药。这项于上周提起并于周一公开的诉讼指控称,安进的生物类似药将侵犯多项专利。根据公司报告,Opdivo去年为百时美施贵宝在美国带来了超过59亿美元的收入。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10